![Christophe Arbet-Engels](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christophe Arbet-Engels
Chief Tech/Sci/R&D Officer at
ALTIMMUNE, INC.
Net worth: 134 529 $ as of 30/06/2026
Profile
Christophe Arbet-Engels is currently a Member of the Biochemical Sciences Tutors Board at Harvard University and will be Chief Medical Officer at Altimmune, Inc. starting in 2025.
Former positions include Vice President-Worldwide Medical at Biogen, Inc., Chief Medical Officer & EVP-Medical Affairs at Poxel SA from 2017 to 2019, Chief Medical Officer at Neurogastrx, Inc. from 2021 to 2023, Chief Medical Officer at Millendo Therapeutics, Inc. from 2020 to 2021, and Chief Medical Officer at X4 Pharmaceuticals, Inc. from 2023 to 2025.
Education includes an MBA from Rutgers State University of New Jersey, graduate studies at Université de Paris XI Paris Sud, and a doctorate from Université de Paris 5 René Descartes.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 12/02/2025 | 28,807 ( 0.03% ) | 134 529 $ | 30/06/2026 |
Christophe Arbet-Engels active positions
| Companies | Position | Start |
|---|---|---|
| ALTIMMUNE, INC. | Chief Tech/Sci/R&D Officer | 01/10/2025 |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Former positions of Christophe Arbet-Engels
| Companies | Position | End |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 16/09/2025 |
Neurogastrx, Inc.
 Neurogastrx, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops transformative therapies for gastrointestinal disorders | Chief Tech/Sci/R&D Officer | 01/08/2023 |
| MILLENDO THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01/01/2021 |
| POXEL | Chief Tech/Sci/R&D Officer | 29/11/2019 |
| BIOGEN INC. | Corporate Officer/Principal | - |
Training of Christophe Arbet-Engels
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
92
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Poxel SA
 Poxel SA Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company, focuses on the development of novel treatments for serious chronic diseases | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université de Paris XI Paris Sud
 Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université de Paris 5 René Descartes
 Université de Paris 5 René Descartes Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Altimmune, Inc.
 Altimmune, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops transformative therapies for gastrointestinal disorders | Health Technology |
Millendo Therapeutics, Inc.
 Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
X4 Pharmaceuticals, Inc.
 X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
- Stock Market
- Insiders
- Christophe Arbet-Engels
